What's Happening?
neuroClues, a French-Belgian medtech company, has raised €10 million in a Series A funding round to support its AI-powered eye-tracking device for early diagnosis of neurological disorders. The device captures infrared images to extract biomarkers indicating
conditions like Parkinson's, Alzheimer's, and multiple sclerosis. With CE certification received in 2025, neuroClues aims for FDA clearance in 2026 and plans to expand into European markets. The funding will enhance the commercial team and support clinical integration of the device.
Why It's Important?
The neuroClues device represents a significant advancement in early diagnosis of neurological disorders, potentially improving patient outcomes by identifying conditions before clinical symptoms appear. The technology addresses the diagnostic gap in Parkinson's disease, where misdiagnosis is common and delays in diagnosis can lead to significant neuronal loss. By providing objective measurements, the device could revolutionize neurological assessments, offering a more precise and early detection method that could be integrated into standard clinical practice.
What's Next?
neuroClues plans to pursue FDA clearance in the U.S. and expand its presence in European markets. The company will focus on building its commercial team and integrating the device into clinical workflows. Future research will explore the device's application in other neurological conditions and its potential to enhance diagnostic accuracy. The funding will support ongoing development and commercialization efforts, positioning neuroClues as a leader in AI-driven neurological diagnostics.
